A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.
This study has been completed.
Sponsor:
Hoffmann-La Roche
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00545402
First received: October 16, 2007
Last updated: October 10, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This 2 arm study will compare the efficacy and safety of two CellCept-containing treatment regimens in de novo liver transplant patients. Patients will be randomized into one of two groups, to receive either CellCept (at a starting dose of 3g/day po, adjusted according to exposure) standard dose tacrolimus and corticosteroids (10-15 mg/kg i.v. on day 0), or fixed dose CellCept 2g/day po, standard dose tacrolimus and corticosteroids (10-15mg/kg i.v. on day 0, then reducing from 20mg to 5mg over 6 months, and discontinuing after 6 months). The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Condition | Intervention | Phase |
---|---|---|
Liver Transplantation |
Drug: mycophenolate mofetil [CellCept] Drug: Tacrolimus Drug: Corticosteroids |
Phase 4 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A Randomized, Open Label Study Comparing the Effect of CellCept With Therapeutic Drug Monitoring, Tacrolimus and a Corticosteroid-sparing Regimen Versus Fixed Dose CellCept, Tacrolimus and Corticosteroids Maintained up to 6 Months, on Acute Rejection and Safety in Liver Transplant Patients. |
Resource links provided by NLM:
MedlinePlus related topics:
Liver Transplantation
Drug Information available for:
Mycophenolic acid
Tacrolimus
Mycophenolate mofetil hydrochloride
Mycophenolate mofetil
U.S. FDA Resources
Further study details as provided by Hoffmann-La Roche:
Primary Outcome Measures:
- Incidence of biopsy-proven and treated acute rejection [ Time Frame: Up to month 12 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Patient and graft survival; histological evaluation of grafts. [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
- Cardiovascular outcomes and renal function [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
- AEs, laboratory parameters. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
Enrollment: | 187 |
Study Start Date: | November 2007 |
Study Completion Date: | February 2012 |
Arms | Assigned Interventions |
---|---|
Experimental: 1 |
Drug: mycophenolate mofetil [CellCept]
3g/day po (starting dose)
Drug: Tacrolimus
Standard, as prescribed
Drug: Corticosteroids
10-15mg/kg iv
|
Experimental: 2 |
Drug: Tacrolimus
Standard, as prescribed
Drug: mycophenolate mofetil [CellCept]
2g/day po (fixed dose)
Drug: Corticosteroids
10-15mg iv reducing to 5mg over 6 months, then discontinuing
|
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- adult patients, >=18 years of age;
- recipient of a first orthotopic liver transplant.
Exclusion Criteria:
- history of organ transplants;
- patient receiving a multi-organ transplant;
- calculated creatinine clearance <=30mL/min before transplant;
- leukocyte count < 2000/mm3 at randomization;
- history of cancer within past 5 years, except for successfully treated basal cell or squamous cell cancer, or in situ cervical cancer;
- pregnant or breast-feeding females, or females of childbearing age not using effective contraception.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00545402
Locations
France | |
Besancon, France, 25030 | |
Bordeaux, France, 33076 | |
Caen, France, 14033 | |
Clichy, France, 92118 | |
Creteil, France, 94010 | |
Grenoble, France, 38043 | |
Lille, France, 59037 | |
Lyon, France, 69317 | |
Lyon, France, 69003 | |
Marseille, France, 13385 | |
Montpellier, France, 34295 | |
Nice, France, 06202 | |
Paris, France, 75014 | |
Rennes, France, 35033 | |
Toulouse, France, 31054 | |
Villejuif, France, 94804 |
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: | Clinical Trials | Hoffmann-La Roche |
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
No publications provided
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00545402 History of Changes |
Other Study ID Numbers: | ML21273 |
Study First Received: | October 16, 2007 |
Last Updated: | October 10, 2012 |
Health Authority: | France:Agence francaise de securite sanitaire des produits de sante (AFSSAPS) |
Additional relevant MeSH terms:
Mycophenolate mofetil Tacrolimus Mycophenolic Acid Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
Pharmacologic Actions Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on October 17, 2012